McKesson Co. (NYSE:MCK) Stock Holdings Trimmed by Csenge Advisory Group

Csenge Advisory Group decreased its stake in shares of McKesson Co. (NYSE:MCK - Free Report) by 20.0% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,934 shares of the company's stock after selling 482 shares during the period. Csenge Advisory Group's holdings in McKesson were worth $1,102,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of MCK. Massachusetts Financial Services Co. MA grew its position in shares of McKesson by 2.9% in the third quarter. Massachusetts Financial Services Co. MA now owns 4,943,520 shares of the company's stock valued at $2,444,175,000 after purchasing an additional 138,685 shares during the period. FMR LLC grew its position in shares of McKesson by 17.3% in the third quarter. FMR LLC now owns 2,968,239 shares of the company's stock valued at $1,467,557,000 after purchasing an additional 438,423 shares during the period. Geode Capital Management LLC grew its position in shares of McKesson by 1.0% in the third quarter. Geode Capital Management LLC now owns 2,653,288 shares of the company's stock valued at $1,306,873,000 after purchasing an additional 26,299 shares during the period. The Manufacturers Life Insurance Company grew its position in shares of McKesson by 55.8% in the third quarter. The Manufacturers Life Insurance Company now owns 1,189,377 shares of the company's stock valued at $588,048,000 after purchasing an additional 425,875 shares during the period. Finally, Nordea Investment Management AB grew its position in shares of McKesson by 20.0% in the fourth quarter. Nordea Investment Management AB now owns 975,935 shares of the company's stock valued at $558,606,000 after purchasing an additional 162,688 shares during the period. Hedge funds and other institutional investors own 85.07% of the company's stock.

Insider Transactions at McKesson

In other news, EVP Leann B. Smith sold 579 shares of McKesson stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $602.81, for a total transaction of $349,026.99. Following the sale, the executive vice president now directly owns 1,443 shares of the company's stock, valued at approximately $869,854.83. The trade was a 28.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Brian S. Tyler sold 8,961 shares of McKesson stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $600.66, for a total value of $5,382,514.26. Following the sale, the chief executive officer now directly owns 69,625 shares in the company, valued at approximately $41,820,952.50. The trade was a 11.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 10,307 shares of company stock valued at $6,177,790. 0.11% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of brokerages have recently commented on MCK. Robert W. Baird raised McKesson from a "neutral" rating to an "outperform" rating and lifted their price objective for the company from $531.00 to $688.00 in a research report on Thursday, November 7th. Citigroup lowered their price objective on McKesson from $713.00 to $677.00 and set a "buy" rating for the company in a research report on Friday, January 10th. Evercore ISI lifted their target price on McKesson from $650.00 to $675.00 and gave the company an "outperform" rating in a report on Thursday, February 6th. Morgan Stanley lifted their target price on McKesson from $612.00 to $642.00 and gave the company an "overweight" rating in a report on Tuesday, December 17th. Finally, Wells Fargo & Company lifted their target price on McKesson from $535.00 to $641.00 and gave the company an "equal weight" rating in a report on Friday, December 13th. Two equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $645.79.

McKesson Trading Down 1.0 %

Shares of MCK traded down $5.83 during midday trading on Friday, reaching $597.68. 671,026 shares of the company were exchanged, compared to its average volume of 745,545. The stock has a 50-day moving average price of $589.02 and a 200-day moving average price of $562.38. The company has a market cap of $74.91 billion, a price-to-earnings ratio of 27.37, a P/E/G ratio of 1.29 and a beta of 0.52. McKesson Co. has a 1-year low of $464.42 and a 1-year high of $637.51.

McKesson (NYSE:MCK - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $8.03 EPS for the quarter, missing analysts' consensus estimates of $8.60 by ($0.57). McKesson had a negative return on equity of 181.26% and a net margin of 0.82%. Equities research analysts anticipate that McKesson Co. will post 32.77 earnings per share for the current year.

McKesson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 1st. Stockholders of record on Monday, March 3rd will be given a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a dividend yield of 0.48%. The ex-dividend date is Monday, March 3rd. McKesson's payout ratio is 13.00%.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.